|Bid||27.02 x 280000|
|Ask||27.33 x 190000|
|Day's range||26.11 - 26.96|
|52-week range||23.43 - 79.72|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||02 Feb 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
SOUTH SAN FRANCISCO, Calif., November 23, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 4:20 p.m. Eastern Time.
Twist Bioscience ( NASDAQ:TWST ) Full Year 2022 Results Key Financial Results Revenue: US$203.6m (up 54% from FY 2021...
Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?